New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
08:08 EDTWWWW, SONS, SIRI, FUN, NVAX, AEGR, WRLD, NRF, ORN, ORB, NCS, DY, CR, PLCE, BIG, SPLKSplunk, Big Lots on FBR's list of stocks that can double
FBR Capital compiled a list of stocks it believes can double within two years. The names on the list are: Big Lots (BIG), Children's Place (PLCE), Crane (CR), Dycom (DY), NCI Building Systems (NCS), Orbital Sciences (ORB), Orion Marine (ORN), Northstar Realty (NRF), World Acceptance (WRLD), Aegerion (AEGR), Novavax (NVAX), Cedar Fair (FUN), Sirius XM (SIRI), Sonus Networks (SONS), Splunk (SPLK) and Web.com (WWWW).
News For SPLK;BIG;PLCE;CR;DY;NCS;ORB;ORN;NRF;WRLD;AEGR;NVAX;FUN;SIRI;SONS;WWWW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:15 EDTSONSSonus sees FY14 EPS 7c, consensus 7c
Subscribe for More Information
07:14 EDTSONSSonus sees Q4 EPS 3c, consensus 3c
Subscribe for More Information
07:13 EDTSONSSonus reports Q3 EPS 1c, consensus 1c
Reports Q3 revenue $73.2M, consensus $71.97M.
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
06:31 EDTWRLDWorld Acceptance experienced lower growth rates due to lower demand in US
Gross loans amounted to $1.19 billion at September 30, 2014, a 2.6% increase over the $1.16 billion outstanding at September 30, 2013, and a 9.0% increase since the beginning of the fiscal year.
06:31 EDTWRLDWorld Acceptance reports Q2 EPS $2.16, consensus $2.30
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.
October 17, 2014
10:00 EDTBIGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:28 EDTNVAXNovavax management to meet with JPMorgan
Subscribe for More Information
08:11 EDTBIGBig Lots initiated with a Buy at Stifel
Target $58.
October 16, 2014
11:15 EDTNVAXHigh option volume stocks
Subscribe for More Information
06:11 EDTORBOrbital raises 2014 adjusted EPS view to $1.20-$1.25 from $1.10-$1.20
Subscribe for More Information
06:08 EDTORBOrbital reports Q3 adjusted EPS 38c, consensus 27c
Subscribe for More Information
05:50 EDTSIRIStocks with implied volatility movement; SHPG SIRI
Subscribe for More Information
October 15, 2014
08:40 EDTNVAXNovavax RSV F Vaccine study evoked polyclonal antibody response
Novavax announced that its RSV F-protein nanoparticle vaccine candidate, or RSV F Vaccine, evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab, resulting in protection from an RSV challenge in an animal model. Researchers at Novavax reported these findings in an online paper published by Vaccine titled: "An insect cell derived respiratory syncytial virus F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization." Greg Glenn, SVP, Research and Development at Novavax stated, "This study further characterizes the immune response to our RSV F Vaccine, including the production of both polyclonal palivizumab competing antibodies that target antigenic site II, as well as other neutralizing antigenic sites on the F-protein. In addition, our ability to assess the safety of our RSV F Vaccine relative to Lot 100 formalin inactivated vaccine, which is known to cause disease enhancement, and to demonstrate that our vaccine's efficacy is equivalent or better than palivizumab, gives us greater confidence that our RSV vaccine candidate will be both safe and effective."
October 14, 2014
16:13 EDTAEGRPoint72 Asset Management reports 5.2% passive stake in Aegerion
Subscribe for More Information
08:40 EDTNVAXNovavax initiates Phase 2 clinical trial of RSV F vaccine
Novavax announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus, or RSV, F-protein nanoparticle vaccine candidate, in healthy elderly subjects. The trial is a randomized, observer-blinded, placebo-controlled Phase 2 study scheduled to enroll 1,600 elderly subjects at ten sites in the United States. The trial will evaluate the incidence of all respiratory illnesses due to RSV, including medically-attended respiratory illnesses due to RSV, and hospitalizations for respiratory illness due to RSV in community-living elderly adults who have been treated with placebo. The study will also evaluate the safety and immunogenicity of a 135g dose of the RSV F Vaccine compared with placebo. The trial will also estimate the efficacy of the RSV F Vaccine in reducing the incidence of respiratory illnesses due to RSV.
October 13, 2014
09:23 EDTSPLKHP could buy lower valuation company, says Bernstein
Subscribe for More Information
06:04 EDTSPLKSplunk upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Splunk to Outperform citing better earnings visibility and more reasonable valuation levels.
October 12, 2014
17:20 EDTSPLKGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use